Hypertension treatment devices maker Kona Medical closed a Series C funding round totaling $40 million in support of its ultrasound-based renal ablation systems.
Unlike other renal ablation systems, Kona’s Surround Sound device uses external ultrasound to non-invasively target the nerves leading to and from the kidney, according to a press release.
"The fully non-invasive system the company is developing may greatly expand access to renal denervation therapy and offer a more patient-friendly alternative for the tens of millions of people who suffer from drug-resistant hypertension," according to a press release.
Funding for the company, which is headquartered bi-coastally in Bellevue, Wash., and Menlo Park, Calif., included new large-cap strategic investors alongside prior funders, Kona noted.
The new financing round brings the total for the year to $70 million, following the $30 million series C the company closed in May.
"We greatly appreciate the interest and support shown by leading healthcare companies and investors," Kona founder & CEO Dr. Michael Gertner said in prepared remarks. "The resources provided by this financing will advance our mission to offer a treatment alternative for the millions of people who suffer from resistant hypertension."